for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Arbutus Biopharma Corp

ABUS.OQ

Latest Trade

0.93USD

Change

-0.00(-0.15%)

Volume

20,496

Today's Range

0.90

 - 

0.94

52 Week Range

0.83

 - 

5.64

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.93
Open
0.93
Volume
20,496
3M AVG Volume
5.40
Today's High
0.94
Today's Low
0.90
52 Week High
5.64
52 Week Low
0.83
Shares Out (MIL)
56.85
Market Cap (MIL)
52.71
Forward P/E
-0.70
Dividend (Yield %)
--

Next Event

Q3 2019 Arbutus Biopharma Corp Earnings Release

Latest Developments

More

Arbutus Biopharma Q2 Loss Per Share $0.46

Veritas Reaches A Mutual Settlement With Arbutus Biopharma Corporation

Arbutus Announces Preliminary Early-Stage Clinical Trial Results For AB-506

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Arbutus Biopharma Corp

Arbutus Biopharma Corp is a Canada-based biopharmaceutical company. The Company is dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The Company develops a portfolio of drug candidates with multiple mechanisms of action that results in a combination therapy to cure HBV. In addition to its HBV pipeline, the Company actively licenses its Lipid Nanoparticle (LNP) technology to its industry partners. This technology represents a delivery technology in RNA interference (RNAi) therapeutic development, which has enabled several clinical trials and has been administered to hundreds of human subjects.

Industry

Biotechnology & Drugs

Contact Info

100-8900 Glenlyon Pky

+1.604.4193200

http://www.arbutusbio.com/

Executive Leadership

Frank M. Torti

Independent Chairman of the Board

William H. Collier

President, Chief Executive Officer, Director

David C. Hastings

Chief Financial Officer

Elizabeth Howard

Executive Vice President, Chief Compliance Officer, General Counsel

Michael Joseph Sofia

Chief Scientific Officer

Key Stats

3.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-4.640

2017

-1.790

2018

-1.210

2019(E)

-1.273
Price To Earnings (TTM)
--
Price To Sales (TTM)
11.47
Price To Book (MRQ)
1.60
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-39.75
Return on Equity (TTM)
-38.03

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up